ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Passage Bio Inc

Passage Bio Inc (PASG)

0.505
-0.031
(-5.78%)
Closed 24 November 8:00AM
0.5186
0.0136
(2.69%)
After Hours: 11:49AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.5186
Bid
0.501
Offer
0.5186
Volume
400,277
0.50 Day's Range 0.5613
0.451 52 Week Range 1.79
Market Cap
Previous Close
0.536
Open
0.54
Last Trade
1
@
0.5186
Last Trade Time
Financial Volume
US$ 207,320
VWAP
0.517941
Average Volume (3m)
250,813
Shares Outstanding
61,767,286
Dividend Yield
-
PE Ratio
-0.30
Earnings Per Share (EPS)
-1.65
Revenue
-
Net Profit
-102.06M

About Passage Bio Inc

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Passage Bio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PASG. The last closing price for Passage Bio was US$0.54. Over the last year, Passage Bio shares have traded in a share price range of US$ 0.451 to US$ 1.79.

Passage Bio currently has 61,767,286 shares in issue. The market capitalisation of Passage Bio is US$33.11 million. Passage Bio has a price to earnings ratio (PE ratio) of -0.30.

PASG Latest News

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from...

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0714-12.10169491530.590.610.4513325280.50262414CS
4-0.0982-15.92088197150.61680.67990.4512136910.57601199CS
12-0.2454-32.12041884820.7640.84990.4512508130.63216187CS
26-0.7614-59.4843751.281.330.4512300590.75602648CS
52-0.082-13.6530136530.60061.790.4513477220.96008081CS
156-7.8414-93.79665071778.368.40.4513067031.82596209CS
260-21.7514-97.671306690622.2738.230.4513039477.46422315CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PDYNPalladyne AI Corporation
US$ 4.59
(129.50%)
83.07M
QMCOQuantum Corporation
US$ 9.11
(126.62%)
39.48M
NANano Labs Ltd
US$ 8.26
(89.02%)
2.03M
XCURExicure Inc
US$ 18.60
(71.27%)
4.59M
SKKSKK Holdings Limited
US$ 1.75
(59.09%)
107.47M
AMIXAutonomix Medical Inc
US$ 6.21
(-54.07%)
946.09k
CETXCemtrex Inc
US$ 0.1146
(-41.74%)
24.39M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
US$ 3.09
(-26.25%)
313.51k
ENSCEnsysce Biosciences Inc
US$ 0.4414
(-25.49%)
4M
ELABElevai Labs Inc
US$ 0.0201
(-0.50%)
425.38M
NVDANVIDIA Corporation
US$ 141.95
(-3.22%)
236.51M
SMCISuper Micro Computer Inc
US$ 33.15
(11.62%)
159.61M
VRPXVirpax Pharmaceuticals Inc
US$ 0.5501
(-6.72%)
159.39M
SOUNSoundHound AI Inc
US$ 8.24
(18.05%)
107.91M

PASG Discussion

View Posts
PonkenPlonken PonkenPlonken 4 months ago
big pop coming. Science hated for no reason. Founder is gene therapy authority. AAV tech works.
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
PASG 10Q due AUGUST5
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 4 months ago
See the first rally on this after the big bar on the first data release. They saw something and took a seat. A lot of shares were bought. Thats because the platform works and will -- veeery surprisingly -- produce great data.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 4 months ago
this is not a daytrade. I am invested here, waiting for the crowd/data.
I think a deal is coming on data release.... its a neglected approach. Founder is a genius and gene therapy authority, popularized AAVs. All the recent bio winners use them.
Happy trading
πŸ‘οΈ0
Awl416 Awl416 4 months ago
Ahem..
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 4 months ago
Going to explode on the next readout

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations


πŸ‘οΈ0
Monksdream Monksdream 5 months ago
There are close to 1,000 listed med tech companies
Only so many can garner serious institutional interest
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 5 months ago
I wonder... when will people realize that the AAV stuff is great... CADL, SLDB, PASG

The founder certainly thinks so... and he is the authority on the topic:
"Dr. James M. Wilson serves as the Director of the Gene Therapy Program (GTP) at Penn's Perelman School of Medicine."

"The Wilson lab identified a new type of vector based on novel isolates of adeno-associated viruses which have become best in class for gene therapy. More recently Dr. Wilson’s laboratory has focused on improved vectors for gene therapy and clinical applications of genome editing and mRNA therapy.The Wilson lab identified a new type of vector based on novel isolates of adeno-associated viruses which have become best in class for gene therapy. More recently Dr. Wilson’s laboratory has focused on improved vectors for gene therapy and clinical applications of genome editing and mRNA therapy."
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
PASG under $2
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
PASG under $2
πŸ‘οΈ0
Sirpeter Sirpeter 8 months ago
Running... boom!!!
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
PASG under $2
πŸ‘οΈ0
glenn1919 glenn1919 8 months ago
PASG..........................https://stockcharts.com/h-sc/ui?s=PASG&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
PASG new 52 week high
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 9 months ago
PASG setting up nicely. Another beautiful call by the only true chartist around
πŸ‘οΈ0
Sirpeter Sirpeter 9 months ago
Yup yup yup...
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 9 months ago
PASG...NEXT CRDL
πŸ‘οΈ0
glenn1919 glenn1919 9 months ago
PASG..............................https://stockcharts.com/h-sc/ui?s=PASG&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 9 months ago
PASG..............................https://stockcharts.com/h-sc/ui?s=PASG&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
PASG under $2
πŸ‘οΈ0
turning stone turning stone 10 months ago
As a new investor in PASG, I am looking forward to another high roller in the next number of years. I bought ARNA years ago at 1.90 and rode it out to $99/share when they were bought out by Phizer Pharm. I would like to have my 5 grandkids share the spoils on this one. With a multi-pipe line, a couple should make it to the end of the line with FDA approval. At the number of shares I purchased multiple times I can afford to run for the hills if a sudden disaster should hit this one. This company is 21 miles from my home and I will stop by shortly and have a sit down with their home-based PR. person. Good luck to all. You may also want to look at BLRX {BIO-Line Inc }










πŸ‘οΈ0
Walter4 Walter4 11 months ago
Data readout should be incoming shortly
👍️ 1
Monksdream Monksdream 1 year ago
PASG new 52 week low
πŸ‘οΈ0
catinhat catinhat 3 years ago
So...anybody out there? Thoughts on upcoming abstract, etc?

Recent long.
πŸ‘οΈ0
dealerschool2006 dealerschool2006 4 years ago
PASG down from panic selling due to the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $22.00 per share.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock